Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGT 53

Next Previous
X
Search
Drug Profile

SGT 53

Alternative Names: p53-gene-therapy-SynerGene; TfRscFv-Liposome-p53 Complex

Latest Information Update: 07 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SynerGene Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference; P53 gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • No development reported Glioblastoma; Solid tumours

Most Recent Events

  • 07 Dec 2022 No development reported - Phase-II for Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA, Taiwan (IV) (NCT02340156)
  • 08 Feb 2022 SynerGene Therapeutics suspends phase I trials in Solid tumours (In adolescents, In adults, In children, In infants, Second-line therapy or greater, Recurrent) in USA (IV) (NCT02354547)
  • 29 Oct 2021 Northwestern University in collaboration with National Cancer Institute (NCI) plans a phase I trial in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater), in the US, in October 2021 (IV) (NCT05093387)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top